摘要
目的 :制备维甲酸固体脂质纳米粒 (RA SLN)并对其药物稳定性进行分析。方法 :以具生物相容性的硬脂酸和棕榈酸作为脂质载体 ,采用溶剂分散法制备维甲酸固体脂质纳米粒 ;测定其平均粒径和zeta电位 ;用透射电镜 (TEM)观察其微观形貌 ;高效液相色谱 (HPLC)法对全反式维甲酸 (ATRA)的浓度进行定量测定 ,并绘出其随时间降解曲线。结果 :以不同脂质材料作为载体制备的RA SLN ,平均粒径 3 0 0～ 40 0nm ,大都呈完整的球形 ,其zeta电位的范围是 -2 8～ -4 0mV ;所制备的RA SLN分散液中有效药物含量在 15mg·L- 1 左右 ,药物降解速度得到降低。结论 :RA SLN提高了有效药物含量 ,改善了药物稳定性 。
Objective To investigate the possibility of retinoic acid solid lipid nanoparticle (RA?SLN) as a new kind of drug carrier to cure proliferative vitreoretinopathy (PVR).Methods RA?SLN was prepared by solvent diffusion method in aqueous system.The mean particle size and zeta potential were decided by PCS method and zeta potential analyzer.Its morphology was examined by transmission electron microscope.The concentrations of all-trans retinoic acid(ATRA) for different time density were determined by high performance liquid chromatography(HPLC) method.Results The mean diameter of RA?SLN was from 300?nm to 400?nm for the different lipid,zeta potential was from -28?mV to -40?mV,drug loading was 15?mg·L -1. Within 4 weeks,the concentration of ATRA was in the range of effective antiproliferation, prolonged the drug release time.Conclusion RA?SLN,a very potential drug carrier increases the drug loading,prolongs the drug releasing time to prevent PVR.
出处
《东南大学学报（医学版）》
CAS
2004年第4期225-227,238,共4页
Journal of Southeast University(Medical Science Edition)
基金
江苏省计委项目 (760 70 380 0 9)
江苏省自然科学基金资助项目 (92 0 70 32 1 1 7)
关键词
维甲酸
固体脂质纳米粒
制备
药物稳定性
溶剂分散法
tretinoin
solid lipid nanoparticle
vitreoretinopathy,proliferative/drug therapy
